Melinta Therapeutics (CEMP) Return on Assets ROA from the third quarter of 2019 to third quarter of 2018 and for the year 2019, Average High and Low, Fundamental Ratios from Sep 30 2019 to Sep 30 2018 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Melinta Therapeutics, Inc.  (CEMP)


Melinta Therapeutics's ROA from the third quarter of 2019 to the third quarter of 2018 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Melinta Therapeutics's ROA in the third quarter of 2019?
Melinta Therapeutics, Inc. recorded a cumulative net loss of $-320 million during 12 months ending in the third quarter of 2019, resulting in a negative return on assets (ROA) of -81.02%.

However, within the Healthcare sector 675 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the second quarter of 2019 from 4044 to 4524.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2019)
III. Quarter		 (Jun 30 2019)
II. Quarter		 (Mar 31 2019)
I. Quarter		 (Dec 31 2018)
IV. Quarter		 (Sep 30 2018)
III. Quarter
Y / Y Total Assets Change -52.62 % -14.43 % 4.84 % 163.11 % 168.12 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -320 -135 -154 -157 -132
Return On Assets (TTM) -81.02 % -29.37 % -32.33 % -33.32 % -32.69 %
CEMP's Total Ranking # 4524 # 4044 # 4146 # 4598 # 4076
Total Assets (TTM) in million 228 440 470 442 482
Seq. Total Assets Change -48.11 % -6.39 % 6.54 % -8.44 % -6.28 %
Seq. Net Income Change - - - - -

CEMP's 5 Years Annual ROA >> Back to CEMP Management Effectiveness >> Compare CEMP ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 336
Sector # 676
Overall # 4343

Return On Assets Statistics
High Average Low
-28.56 %
-44.07 %
-81.02 %
(Mar 31 2017)   (Sep 30 2019)





Financial Statements
Melinta Therapeutics's Assets $ 228 million CEMP's Balance sheet
Melinta Therapeutics's Income $ -213 million Quarterly CEMP's Income Statement
CEMP's Income by Division See CEMP's Income by Division



Annual Return On Assets (Dec 31 2018)
FY 2018		 (Dec 31 2017)
FY 2017		 (Dec 31 2016)
FY 2016		 (Dec 31 2015)
FY 2015		 (Dec 31 2014)
FY 2014
Y / Y Total Assets Change 175.52 % -32.8 % 47.11 % 53.96 % 6.37 %
Total Assets in million 442 160 239 162 105
Y / Y Net Income Change - - - - -
Net Income in million -157 -78 -118 -91 -62
Annual Return On Assets -35.6 % -48.78 % -49.46 % -56.19 % -58.54 %

CEMP's 5 Years Annual ROA >> Back to CEMP Management Effectiveness >> Compare CEMP ROA to its Competitors



More Return On Assets Ratios
CEMP's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CEMP's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CEMP's Competitors
Subscribers only: Roa for Melinta Therapeutics's Suppliers
Subscribers only: Return On Assets for CEMP's Customers

You may also want to know
CEMP's Roi CEMP's Inventory Turnover Ratio CEMP's Growth Rates CEMP's Dividend Comparisons
CEMP's Profitability Ratios CEMP's Asset Turnover Ratio CEMP's Dividend Growth
CEMP's Roe CEMP's Valuation Ratios CEMP's Financial Strength Ratios CEMP's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2019, within Healthcare Sector ROA

Date modified: 2026-09-26T06:56:48+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.